Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

sease.

ABH001 is comprised of allogenic neonatal dermal fibroblasts seeded on a poly(glycolide-co-L-lactide) scaffold, and is currently approved and marketed in the United States as a Class III medical device under the trade name Dermagraft® for the treatment of diabetic foot ulcers.

About Epidermolysis Bullosa (EB)

Epidermolysis Bullosa is a family of genetic skin fragility disorders, primarily clinically characterized by blistering of the skin in response to friction or minor trauma. Although genetically and phenotypically heterogeneous, the common factor in all EB patients is the near constant presence of skin erosions and wounds. Severe forms of EB cause patients to live with constant pain and scarring, and may be fatal.

About ABH001

ABH001 is a tissue-engineered, human fibroblast-derived dermal substitute generated by culturing human neonatal dermal fibroblasts onto a bioabsorbable polyglactin (PGLLA) mesh scaffold. The fibroblasts, which are grown onto the PGLLA mesh, secrete dermal collagen, other extracellular matrix proteins, growth factors, and cytokines, creating a three-dimensional human tissue containing metabolically active living cells. The final product consists of a well-developed dermal matrix and evenly dispersed neonatal dermal fibroblasts.

About Dermagraft

Dermagraft is indicated for use in the treatment of full-thickness diabetic foot ulcers greater than six weeks duration, which extend through the dermis, but without tendon, muscle, joint capsule, or bone exposure. Dermagraft should be used in conjunction with standard wound care regimens and in patients that have adequate blood supply to the involved foot. Dermagraft is contraindicated for use in ulcers that have signs of clinical infection or in ulcers with sinus tracts. Dermagraft is contraindicated in patients with known hypersensitivity to bovine products, as it may contain trace amounts of bovine p
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... two investor conferences in the month of September.  ... Officer, will present at Rodman & Renshaw,s 17th Annual ... 10:25am ET/7:25am PT at the St. Regis Hotel in ...
(Date:8/27/2015)... YORK , August 27, 2015 ... enhancing image processing functions in the human vision system, announced ... point guard Chris Paul to develop ... players who want to improve their real-life on-court performance. ... the court, whether it is shooting a ball or blocking ...
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
(Date:7/31/2015)... , 31 de julho de 2015 ... www.icg-10.org ) será realizada pela BGI de 22-25 de ... . A conferência está celebrando seu 10 ... 2006, a ICG se tornou uma das reuniões mais ... dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... A team of biologists from UC San Diego, the Salk ... the genes that enable plants to undergo bursts of rhythmic ... leaves are shaded by other plants. The researchers report ... that these genes control the complex interplay of plant ...
... as a biofuels source has a much longer growing ... secret of its success. Their findings offer a promising ... significantly boost per-acre yields. The new study, from ... Plant Physiology Preview . Miscanthus x giganteus ...
... of glowing red. Research published today in BMC ... red light. Due to absorption of ,red, wavelengths ... normal conditions appear grey or black at depths below ... biologists that red colours are of no importance to ...
Cached Biology News:Biologists identify genes controlling rhythmic plant growth 2Biologists identify genes controlling rhythmic plant growth 3Biologists identify genes controlling rhythmic plant growth 4Giant grass offers clues to growing corn in cooler climes, researchers report 2
... is the industry standard microarray image analysis ... imaging and analysis tools, visualizations, automation capabilities, ... is included with every GenePix scanner, and ... scanners and all types of arrays. A ...
... is the ideal instrument for budget-conscious labs that ... applications. Get Applied Biosystems proven PCR ... lab space without sacrificing results. Enhance ... Technology You Can Afford The Applied ...
... synthesis with a wide variety of purity levels, ... needs. Purity: IG(>50%), >70%, >80% ... Sequence Length: Up to 120 residues ... phosphorylation, D-amino acids, MAPs, KLH/BSA conjugation, and much ...
... The AquaMax DW4 liquid handling system from ... washing all in one instrument. The system ... dispensing and plate washing96-, 384- and 1536-welland ... washing. AquaMax DW4 has been optimized to ...
Biology Products: